A double-blind, single dose, four period, crossover study to demonstrate the equivalence between the two HFA formulations of formoterol fumarate; using serial spirometry measurements for 12 hrs Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009
Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Changes in subjective assessments during 2 and 4 weeks of a nasal CPAP (nCPAP) trial? Source: Eur Respir J 2002; 20: Suppl. 38, 101s Year: 2002
Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020 Year: 2021
The REACH study, a randomized controlled trial assessing the safety and effectiveness of the Spiration Valve System endobronchial therapy for severe emphysema: 12 month follow-up results. Source: International Congress 2017 – Interventional pulmonology highlights 2017 Year: 2017
Audit of inter-spirometer reproducibility of FEV1 in 4 spirometers over 20 measurement days. Observation of variability in FEV1 in a normal subject over 20 measurement days Source: Eur Respir J 2007; 30: Suppl. 51, 180s Year: 2007
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial Source: ERJ Open Res, 5 (2) 00032-2019; 10.1183/23120541.00032-2019 Year: 2019
Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018
Comparison against baseline in randomised control trials (again) Source: Eur Respir J 2014; 44: 1376 Year: 2014
Comparison against baseline in randomised control trials (again) Source: Eur Respir J 2014; 44: 1376-1377 Year: 2014
Arformoterol in COPD: safety results from two pooled phase 3 trials Source: Eur Respir J 2006; 28: Suppl. 50, 428s Year: 2006
A phase 1, single-center, open-label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019
Effects of exercise training after lung transplantation: 1 year follow-up of a randomized controlled trial Source: Annual Congress 2011 - Exercise training: new populations, new techniques Year: 2011
A multicenter, randomised, double-blind, placebo-controlled 6 month trial to evaluate efficacy and tolerability of bupropion hydrochloride sustained release (SR) tablets as treatment for nicotine dependency in healthcare workers and as an aid to smoking Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: The ENLIGHTEN study Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD Year: 2012